Table 1.
Clinical characteristics of patients with CLL
| No. patients (%) | |
|---|---|
| Rai stage | |
| Low risk (stage 0) | 25 (21%) |
| Intermediate-risk (stage I/II) | 73 (61%) |
| High-risk (stage III/IV) | 21 (18%) |
| ZAP-70 (cut-off 20%) | |
| Positive (%) | 51 (43%) |
| Negative (%) | 68 (57%) |
| CD38 (cut-off 30%) | |
| Positive (%) | 48 (40%) |
| Negative (%) | 71 (60%) |
| Cytogenetic abnormalities | |
| del(17p13.1) and/or del(11q22.3) | 49 (41.18%) |
| Isolated del(13q14) | 35 (29.41%) |
| Without del(17p13.1) and del(11q22.3) and del(13q14) | 29 (24.37%) |
| Not evaluated | 6 (5.04%) |
| Patients requiring therapy | 51 (42.9%) |
| Untreated patients | 68 (57.1%) |
| Median (min–max) | |
|---|---|
| Age at diagnosis (years) | 65 (49–87) |
| WBC count (G/L) | 29.53 (8.72–330.56) |
| Lymphocyte count (G/L) | 20.07 (5.51–317.85) |
| β2M (mg/dL) | 2.39 (1.36–5.86) |
| LDH (IU/L) | 355 (265–886) |
| Hemoglobin (g/dL) | 13.6 (9.2–16.5) |
| Platelets (G/L) | 174 (49–388) |
| CD19+/CD5+/ZAP-70+ cells (%) | 24.64 (0.21–64.29) |
| CD19+/CD5+/CD38+ cells (%) | 29.42 (0.22–80.90) |
WBC white blood cell, LDH lactate dehydrogenase, β2M β2-microglobulin